GlassScriptPhysician profile
Jared T Brownfield
NPI 1730448291
$2,137.28
in general payments reported to CMS, 2019-2025
36 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $172 · 2021: $447 · 2022: $288 · 2023: $388 · 2024: $209 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.23 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $216.61 | 2021-2024 | Otezla, Repatha, Tezspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.07 | 2019-2021 | |
| Abbvie INC. | $189.61 | 2019-2021 | |
| Esperion Therapeutics, INC. | $118.80 | 2021-2022 | |
| Therapeuticsmd, INC. | $114.35 | 2019-2022 | |
| Abbott Laboratories | $101.01 | 2023 | Proclaim |
| Lilly USA, LLC | $98.59 | 2023-2025 | Jardiance, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $96.26 | 2021-2025 | |
| Daiichi Sankyo INC. | $89.67 | 2022-2024 | Injectafer |
| Vifor Pharma, INC. | $76.20 | 2021-2023 | Veltassa, Korsuva |
| Avanir Pharmaceuticals, INC. | $75.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.61 | 2019-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $64.20 | 2022-2023 | Ultomiris |
| Amarin Pharma, INC. | $58.22 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.25 | 2021-2023 | Glassia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $53.69 | 2024 | |
| Sunovion Pharmaceuticals INC. | $47.57 | 2021 | |
| Tactile Systems Technology INC | $42.15 | 2025 | Flexitouch Plus, Nimbl |
| Pfizer INC. | $37.44 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $32.06 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $30.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $29.80 | 2022-2023 | Farxiga |
| Coopersurgical, INC. | $25.30 | 2020 | |
| Argenx US, INC. | $22.76 | 2023 | Vyvgart |
| Xeris Pharmaceuticals, INC. | $22.08 | 2022 | |
| Kyowa Kirin, INC. | $21.48 | 2025 | |
| Paratek Pharmaceuticals, INC. | $19.88 | 2024 | Nuzyra |
| Scpharmaceuticals INC. | $19.26 | 2025 | |
| Astellas Pharma US INC | $17.12 | 2024 | Veozah |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Hologic Sales and Service, LLC | $14.99 | 2025 | Novasure, Fluent Fluid Management System, Myosure Tissue Removal Device |
| Boston Scientific Corporation | $14.40 | 2024 | Watchman Flx |
| Sage Therapeutics, LLC | $13.13 | 2024 | |
| Janssen Biotech, INC. | $13.09 | 2024 | Tremfya |
| Corcept Therapeutics | $12.93 | 2021 | |
| Novo Nordisk INC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Brownfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.